Clinical trial
A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy…
NCT00466440 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00466440 |
|---|---|
| Title | A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients |
| Official title | A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study With and Without Enzastaurin in Combination With Docetaxel and Prednisone, Followed By Enzastaurin Maintenance as First-Line Treatment in Hormone Refractory Metastatic Prostate Cancer Patients |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | enzastaurin, placebo, docetaxel, prednisone |
| Enrollment | 108 |
| Start date | Jun 1, 2007 |
| Primary completion | Aug 1, 2009 |
| Completion | Jun 1, 2010 |
| First posted | Apr 27, 2007 |
| Last update posted | Nov 6, 2020 |
| Countries | Germany, Italy, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: